Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Clin Cancer Res. 2019 Dec 3;26(7):1563–1573. doi: 10.1158/1078-0432.CCR-19-2685

Figure 4.

Figure 4.

Age-based cyclophosphamide dosing adjustment simulations to attain similar 4OH-CTX plasma exposure (AUC0–24h) across pediatrics. (A) 4OH-CTX exposure ranges (AUC0–24h) after a 1-hour infusion of cyclophosphamide (1.5 g/m2) in young infants (< 6 months), infants (0.5–1 year), toddlers (1–2 years), and young children (2–5 years). (B) 4OH-CTX AUC0–24h ranges after de-escalated cyclophosphamide dosages in young infants vs. 4OH-CTX AUC0–24h obtained in young children receiving 1.5 g/m2 cyclophosphamide. (C) 4OH-CTX AUC0–24h ranges after de-escalated cyclophosphamide dosages in infants vs. 4OH-CTX AUC0–24h obtained in young children receiving 1.5 g/m2 cyclophosphamide. (D) 4OH-CTX AUC0–24h ranges after de-escalated cyclophosphamide dosages in toddlers vs. 4OH-CTX AUC0–24h obtained in young children receiving 1.5 g/m2 cyclophosphamide. P values results from Dunnett’s multiple comparisons tests.